1
Clinical Trials associated with Double Negative T Cells(Ozmosis Research)Phase I Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia
This study aims to determine the safety and toxicity of incremental doses of Double Negative T (DNT) cells in human subjects with high risk acute myeloid leukemia (AML). DNT cells are mature T lymphocytes that comprise
1% of white blood cells in humans. Injection of DNTs from healthy donors has been demonstrated to be effective against AML cells. DNT cells will be collected from healthy volunteers and injected into patients.
100 Clinical Results associated with Double Negative T Cells(Ozmosis Research)
100 Translational Medicine associated with Double Negative T Cells(Ozmosis Research)
100 Patents (Medical) associated with Double Negative T Cells(Ozmosis Research)
100 Deals associated with Double Negative T Cells(Ozmosis Research)